Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.

BMY : 48.16 (-1.55%)
Next Support Level for Bristol-Myer Sqb (BMY) is $48.74

Shares of Bristol-Myer Sqb (NYSE:BMY) opened today below their pivot of $49.04 and have already reached the first level of support at $48.92. Analysts will be watching for a cross of the next downside...

BMY : 48.16 (-1.55%)
Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market

Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

AZN : 42.59 (-0.84%)
MRK : 82.29 (-0.80%)
PFE : 41.85 (-1.18%)
BMY : 48.16 (-1.55%)
Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition

The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.

CELG : 88.15 (-1.65%)
MRK : 82.29 (-0.80%)
RHHBY : 33.7600 (-1.06%)
BMY : 48.16 (-1.55%)
Brain Cancer Study of Viral and Checkpoint Immunotherapy Initiates Accrual

Candel Therapeutics (a.k.a. Advantagene, Inc.) announced today the treatment of the first high grade glioma patients in a study of its Gene Mediated Cytotoxic Immunotherapy (GMCI(TM); aglatimagene besadenovec...

BMY : 48.16 (-1.55%)
Global Hodgkin's Lymphoma Drugs Market Outlook, 2019 to 2023 - Bristol-Myers Squibb Company, Merck & Co, Ono Pharmaceutical Co, Pfizer, and Seattle Genetics are Dominating - ResearchAndMarkets.com

The "Global Hodgkin's Lymphoma Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

MRK : 82.29 (-0.80%)
BMY : 48.16 (-1.55%)
OPHLF : 28.8300 (+1.55%)
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Bristol-Myers Squibb (BMY) closed the most recent trading day at $49.21, moving -0.78% from the previous trading session.

BMY : 48.16 (-1.55%)
Look for Shares of Bristol-Myer Sqb to Potentially Rebound after Yesterday's 1.55% Sell Off

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $48.83 to a high of $49.59. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $48.84...

BMY : 48.16 (-1.55%)
SmarTrend Watching for Potential Rebound in Shares of Bristol-Myer Sqb After 1.55% Loss

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $48.83 to a high of $49.59. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $48.84...

BMY : 48.16 (-1.55%)
Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study

Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.

MRK : 82.29 (-0.80%)
PFE : 41.85 (-1.18%)
MKGAF : 112.8500 (+0.09%)
BMY : 48.16 (-1.55%)
Global Gynecological Cancers Therapeutics Market Forecast 2019-2023, with AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, GlaxoSmithKline, Merck & Co. Dominating - ResearchAndMarkets.com

The "Global Gynecological Cancers Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

MRK : 82.29 (-0.80%)
BMY : 48.16 (-1.55%)
Atopic Dermatitis Market Highest Growth in Healthcare with Size, Share, Price Trend, Foreseen by 2023

VRX.TO : 30.80 (-3.33%)
ANAC : 99.06 (-0.14%)
AGN : 149.30 (-2.76%)
ALPMF : 15.6300 (+1.26%)
NVS : 93.42 (-0.26%)
REGN : 391.80 (-2.68%)
PFE : 41.85 (-1.18%)
BMY : 48.16 (-1.55%)
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

AZN : 42.59 (-0.84%)
MRK : 82.29 (-0.80%)
RHHBY : 33.7600 (-1.06%)
BMY : 48.16 (-1.55%)
Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition of Celgene

Starboard Value LP (together with its affiliates, "Starboard"), a stockholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company")(NYSE: BMY), today announced that it has issued an investor...

CELGZ : 1.25 (-0.80%)
BMY : 48.16 (-1.55%)
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger...

CELG : 88.15 (-1.65%)
CELGZ : 1.25 (-0.80%)
BMY : 48.16 (-1.55%)
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).

CELG : 88.15 (-1.65%)
BDSI : 5.11 (-3.58%)
PFE : 41.85 (-1.18%)
BMY : 48.16 (-1.55%)
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

AZN : 42.59 (-0.84%)
NVS : 93.42 (-0.26%)
GSK : 41.25 (+0.02%)
BMY : 48.16 (-1.55%)
AUGUSTUS Demonstrates Favorable Safety Results of Eliquis(R) Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

The Bristol-Myers Squibb-Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis(R) (apixaban) versus vitamin K antagonists (VKAs) in patients...

PFE : 41.85 (-1.18%)
BMY : 48.16 (-1.55%)
Keloid Treatment Market Outlook, Opportunity by 2024

New York, March 15, 2019: Global is segmented based on the treatments type as, Occlusive Dressing, Compression Therapy, Cryosurgery, Excision, Radiation Therapy, Laser Therapy, Interferon Therapy, Intralesional...

VRX.TO : 30.80 (-3.33%)
GALE : 0.26 (-7.14%)
AVMXY : 4.0200 (+13.88%)
NVS : 93.42 (-0.26%)
SNOA : 0.98 (unch)
GSK : 41.25 (+0.02%)
BMY : 48.16 (-1.55%)
PRGO : 47.25 (-2.74%)
Infinity Inks Deal With Roche for Phase II Study of IPI-549

Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.

RCUS : 11.19 (-5.65%)
INFI : 1.76 (+2.33%)
RHHBY : 33.7600 (-1.06%)
BMY : 48.16 (-1.55%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar